Cabotegravir is an investigational integrase inhibitor in development for the 
treatment and pre-exposure prophylaxis of HIV-1 infection. Liver disease is a 
major cause of morbidity and mortality in HIV-infected individuals and can 
impact the pharmacokinetics (PK) of HIV medications. This phase 1 study 
evaluated the PK of cabotegravir in individuals with moderate hepatic impairment 
(n = 8) versus healthy controls (n = 8). Participants received a single oral 
cabotegravir 30-mg tablet and underwent PK sampling to determine total and 
unbound plasma cabotegravir concentrations. Calculated geometric least-squares 
mean ratios (90% confidence intervals) for individuals with hepatic impairment 
versus healthy controls were 0.73 (0.50-1.06) for AUC0-∞ , 0.69 (0.51-0.93) for 
Cmax , 1.40 (0.80-2.46) for unbound concentration (CU) 2 hours postdose, 1.55 
(0.82-2.94) for CU at 24 hours, 2.14 (1.57-2.90) for unbound fraction (FU) at 
2 hours, and 1.90 (1.14-3.18) for FU at 24 hours. Adverse events (AEs) occurred 
in 2 individuals with hepatic impairment and 3 healthy controls and were grade 
1/2 in severity. No participant discontinued because of AEs. Increased FU 
resulted in a modest decrease in total plasma exposure not considered clinically 
relevant. We conclude that cabotegravir may be administered without dose 
adjustment in patients with mild to moderate hepatic impairment.